Poly(lactic-co-glycolic acid) is a copolymer which is used in a wide array of FDA approved therapeutic devices. PLGA is a biodegradable, biocompatibility polymer that by hydrolysis of its ester linkages in the presence of water. It has been shown that the time required for degradation of PLGA is related to the monomers’ ratio used in production: the higher the content of glycolide units, the lower the time required for degradation.

We can produce microparticles in with average sizes of 30 um or 5 um. We have developed proprietary technology to allow us to incorporated hydrophobic drugs with the ability to tailor the drug loading from 10% to 40% w/w. In-vitro release profiles for our hydrophobic drugs shows in-vitro release of the drug for over 6 months.

We have also developed technology to incorporate peptides into the microparticles and have shown therapeutic effects in rat models for 4 weeks.

30 um microparticles5 um microparticles

Sustained Release

Preclinical Ophthalmic Contract Research